Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results


- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -

See the original post here:
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Related Posts